专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5955477A Methods for treating gastrointestinal motility dysfunction using optically pure (--) cisapride 失效
标题翻译：使用光学纯（ - ）西沙必利治疗胃肠蠕动功能障碍的方法
公开(公告)号：US5955477A
公开(公告)日：1999-09-21
申请号：US752984
申请日：1996-11-21
申请人： Nancy M. Gray , James W. Young
发明人： Nancy M. Gray , James W. Young
IPC分类号： C07D211/62 , A61K31/445 , A61K31/4468 , A61P1/00 , A61P1/08 , A61P1/10 , A61P1/14
CPC分类号： A61K31/445 , A61K31/4468
摘要： The optically pure (-) isomer of cisapride is useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (-) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (-) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.
摘要翻译：西沙必利的光学纯（ - ）异构体可用于治疗消化不良和其他可能与（ - ）西沙必利作为促动力剂如胃轻瘫，便秘，手术后肠梗阻和肠道活动有关的其他病症假性梗阻，没有与西沙必利的外消旋混合物有关的副作用的伴随的责任。西沙必利的（ - ）异构体也表现出比外消旋西沙必利更长的作用时间，并且可用于治疗中枢神经系统疾病。

2. 发明授权

US5888535A Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole 失效
标题翻译：使用光学纯（ - ）泮托拉唑治疗胃疾病的方法和组合物
公开(公告)号：US5888535A
公开(公告)日：1999-03-30
申请号：US772944
申请日：1996-12-23
申请人： Nancy M. Gray
发明人： Nancy M. Gray
IPC分类号： C07D401/12 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61P1/04 , A61K9/127
CPC分类号： A61K31/4439 , A61K31/44
摘要： Methods and compositions are disclosed utilizing optically pure (-) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (-) isomer is also useful for the treatment of gastroesophageal reflux. (-) Pantoprazole is an inhibitor of H.sup.+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
摘要翻译：公开了使用光学纯的（ - ）泮托拉唑用于治疗人类溃疡的方法和组合物，同时显着降低与泮托拉唑的外消旋混合物相关的副作用的伴随的责任。光学纯的（ - ）异构体也可用于治疗胃食管反流。（ - ）泮托拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

3. 发明授权

US5629337A Methods for treating asthma using optically pure (-)-zileuton 失效
标题翻译：使用光学纯（ - ） - 齐来顿治疗哮喘的方法
公开(公告)号：US5629337A
公开(公告)日：1997-05-13
申请号：US369254
申请日：1995-01-05
申请人： Nancy M. Gray
发明人： Nancy M. Gray
IPC分类号： C07D333/58 , A61K31/38 , A61K31/381 , A61P1/00 , A61P9/10 , A61P11/00 , A61P17/00 , A61P27/16 , A61P29/00 , A61P35/00 , A61P37/08 , A61P43/00
CPC分类号： A61K31/38 , A61K31/381
摘要： Methods are disclosed utilizing optically pure (-)-zileuton for the treatment of asthma in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of zileuton.
摘要翻译：公开了利用光学纯的（ - ） - 齐鲁汤治疗人类哮喘的方法，同时显着减少与齐育酮的外消旋混合物相关的副作用的伴随的责任。

4. 发明授权

US5629329A Methods for treating disorders associated with the central nervous system using opticallly pure (+) cisapride 失效
标题翻译：使用光学纯（+）西沙必利治疗与中枢神经系统相关疾病的方法
公开(公告)号：US5629329A
公开(公告)日：1997-05-13
申请号：US690242
申请日：1996-07-19
申请人： Nancy M. Gray , James W. Young
发明人： Nancy M. Gray , James W. Young
IPC分类号： C07D211/62 , A61K31/445 , A61K31/4468 , A61P1/00 , A61P1/08 , A61P1/10 , A61P1/14 , A61K31/395 , C07D409/06
CPC分类号： A61K31/445 , A61K31/4468
摘要： Methods are disclosed utilizing the optically pure (+) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of cisapride. This compound is also useful in treating or preventing emesis while substantially reducing adverse effects associated with racemic cisapride. The optically pure (+) isomer of cisapride is also useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (+) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (+) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.
摘要翻译：公开利用西沙必利的光学纯（+）异构体的方法。该化合物是用于治疗胃食管反流疾病的有效药物，同时显着减少与西沙必利的外消旋混合物相关的副作用的伴随的责任。该化合物也可用于治疗或预防呕吐，同时显着降低与西西沙必利素有关的不良反应。西沙必利的光学纯的（+）异构体也可用于治疗消化不良和其它可能与（+）西沙必利作为促动力剂的活性相关的其它病症，例如胃轻瘫，便秘，手术后肠梗阻和肠假性梗阻，没有与西沙必利的外消旋混合物相关的副作用的伴随的责任。西沙必利的（+）异构体也表现出比外消旋西沙必利更长的作用时间，并且可用于治疗中枢神经系统疾病。

5. 发明授权

US5137910A Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders 失效
标题翻译：含有吲哚-2-羧酸盐化合物的组合物，用于治疗中枢神经系统疾病
公开(公告)号：US5137910A
公开(公告)日：1992-08-11
申请号：US484530
申请日：1990-03-01
申请人： Nancy M. Gray , Brian K. Cheng , William F. Hood , Michael S. Dappen , Alex A. Cordi
发明人： Nancy M. Gray , Brian K. Cheng , William F. Hood , Michael S. Dappen , Alex A. Cordi
IPC分类号： A61K31/405
CPC分类号： A61K31/405
摘要： Compositions containing certain indole-2-carboxylate compounds and derivatives are described as being therapeutically effective in treatment of CNS disorders resulting from neurotoxic damage or neurodegenerative diseases, particularly those CNS disorders resulting from ischemic events. Preferred compounds are of the formula ##STR1## wherein each of R.sup.5 and R.sup.6 is independently selected from hydrido, bromo, chloro and fluoro, and wherein each of R.sup.10 and R.sup.12 is independently selected from hydrido and lower alkyl, and pharmaceutically-acceptable salts thereof.
摘要翻译：含有某些吲哚-2-羧酸酯化合物和衍生物的组合物被描述为治疗由神经毒性损伤或神经变性疾病，特别是由缺血事件引起的CNS障碍引起的CNS障碍的治疗有效性。优选的化合物具有式“IMAGE”，其中R 5和R 6各自独立地选自氢，溴，氯和氟，并且其中R 10和R 12各自独立地选自氢和低级烷基及其药学上可接受的盐。

6. 发明授权

US5055468A Use of bridged tricyclic amine derivatives as anti-ischemic agents 失效
标题翻译：桥联三环胺衍生物作为抗缺血剂的用途
公开(公告)号：US5055468A
公开(公告)日：1991-10-08
申请号：US428531
申请日：1989-10-30
申请人： Nancy M. Gray , Patricia C. Contreras
发明人： Nancy M. Gray , Patricia C. Contreras
IPC分类号： A61K31/135 , A61K31/16 , A61K31/445 , A61K31/495 , A61K31/505
CPC分类号： A61K31/16 , A61K31/135 , A61K31/445 , A61K31/495 , A61K31/505
摘要： Certain bridged tricyclic amine compounds are described as being therapeutically effective in treatments of CNS disorders resulting from neurotoxic damage or neurodegenerative diseases, particularly those CNS disorders resulting from ischemic events. Compounds of particular interest for use as neuroprotective agents are those of the formula ##STR1## wherein each of R.sup.1 and R.sup.2 is independently selected from hydrido, loweralkyl, benzyl and phenyl; wherein each of R.sup.1 through R.sup.7 is independently selected from hydrido, loweralkyl, hydroxy, benzyl, phenyl, loweralkoxy, phenoxy, benzyloxy, halo and haloloweralkyl; wherein R.sup.18 may be selected from hydrido, loweralkyl, cycloalkyl of five or six carbon atoms, cycloalkylalkyl of six or seven carbon atoms, phenyl, hydroxyloweralkyl, and heteroaryl selected from saturated or fully unsaturated heterocyclic rings containing five to seven ring members of which one or two ring members are nitrogen atom; wherein each X is independently one or more groups selected from hydrido, hydroxy, loweralkyl, benzyl, phenyl, loweralkoxy, phenoxy, haloloweralkyl, halo, and lower-alkanoyl; and wherein each of R.sup.23 through R.sup.30 is independently selected from hydrido, lower alkyl, benzyl, phenyl and halo; wherein R.sup.18 together with one of R.sup.23, R.sup.24, R.sup.29 or R.sup.30 may form a fused heterocyclic ring containing five or six ring members; or a pharmaceutically-acceptable salt thereof.
摘要翻译：描述了某些桥连的三环胺化合物在治疗由神经毒性损伤或神经变性疾病，特别是由缺血事件引起的CNS障碍引起的CNS障碍中的治疗有效性。用作神经保护剂的特别感兴趣的化合物是下式的化合物：其中R 1和R 2各自独立地选自氢，低级烷基，苄基和苯基; 其中R 1至R 7各自独立地选自氢，低级烷基，羟基，苄基，苯基，低级烷氧基，苯氧基，苄氧基，卤代和卤代低级烷基; 其中R 18可以选自氢或低级烷基，5或6个碳原子的环烷基，6或7个碳原子的环烷基烷基，苯基，羟基低级烷基和选自饱和或完全不饱和的含有5-7个环成员的杂环，其中一个或两个环成员是氮原子; 其中每个X独立地是一个或多个选自氢，羟基，低级烷基，苄基，苯基，低级烷氧基，苯氧基，卤代低级烷基，卤素和低级烷酰基的基团。并且其中R 23至R 30各自独立地选自氢，低级烷基，苄基，苯基和卤素; 其中R 18与R 23，R 24，R 29或R 30中的一个可以形成含有五个或六个环成员的稠合杂环; 或其药学上可接受的盐。

7. 发明授权

US06953808B2 Method for treating gastric disorders using optically pure (−) pantoprazole 失效
标题翻译：使用光学纯（ - ）泮托拉唑治疗胃病的方法
公开(公告)号：US06953808B2
公开(公告)日：2005-10-11
申请号：US10757059
申请日：2004-01-14
申请人： Nancy M. Gray
发明人： Nancy M. Gray
IPC分类号： C07D401/12 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61P1/04
CPC分类号： A61K31/4439 , A61K31/44
摘要： Methods and compositions are disclosed utilizing optically pure (−) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Pantoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
摘要翻译：公开了使用光学纯的（ - ）泮托拉唑用于治疗人类溃疡的方法和组合物，同时显着降低与泮托拉唑的外消旋混合物相关的副作用的伴随的责任。光学纯的（ - ）异构体也可用于治疗胃食管反流。（ - ）泮托拉唑是释放H +的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症如Zollinger-Ellison综合征。

8. 发明授权

US5955478A Methods for treating gastrointestinal motility dysfunction using optically pure (+) cisapride 失效
标题翻译：使用光学纯（+）西沙必利治疗胃肠蠕动功能障碍的方法
公开(公告)号：US5955478A
公开(公告)日：1999-09-21
申请号：US754657
申请日：1996-11-21
申请人： Nancy M. Gray , James W. Young
发明人： Nancy M. Gray , James W. Young
IPC分类号： C07D211/62 , A61K31/445 , A61K31/4468 , A61P1/00 , A61P1/08 , A61P1/10 , A61P1/14
CPC分类号： A61K31/445 , A61K31/4468
摘要： Methods are disclosed utilizing the optically pure (+) isomer of cisapride. The optically pure (+) isomer of cisapride is useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (+) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (+) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.
摘要翻译：公开利用西沙必利的光学纯（+）异构体的方法。西沙必利的光学纯（+）异构体可用于治疗消化不良和其他可能与（+）西沙必利作为促动力剂的活性相关的其它病症，如胃轻瘫，便秘，手术后肠梗阻和肠假性梗阻，没有与西沙必利的外消旋混合物相关的副作用的伴随的责任。西沙必利的（+）异构体也表现出比外消旋西沙必利更长的作用时间，并且可用于治疗中枢神经系统疾病。

9. 发明授权

US5627183A Methods for treating urticaria using optically pure (+) cetirizine 失效
标题翻译：使用光学纯（+）西替利嗪治疗荨麻疹的方法
公开(公告)号：US5627183A
公开(公告)日：1997-05-06
申请号：US622617
申请日：1996-03-26
申请人： Nancy M. Gray
发明人： Nancy M. Gray
IPC分类号： C07D241/04 , A61K31/495 , A61P11/00 , A61P37/08
CPC分类号： A61K31/495
摘要： Methods are disclosed utilizing optically pure (+) cetirizine for the treatment of urticaria in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine.
摘要翻译：公开了利用光学纯（+）西替利嗪治疗人类荨麻疹的方法，同时避免与西替利嗪的外消旋混合物相关的副作用的伴随的责任。

10. 发明授权

US5508279A Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia 失效
标题翻译：（+）多沙唑嗪治疗良性前列腺增生的方法和组成
公开(公告)号：US5508279A
公开(公告)日：1996-04-16
申请号：US206764
申请日：1994-03-07
申请人： Nancy M. Gray
发明人： Nancy M. Gray
IPC分类号： C07D405/12 , A61K9/20 , A61K9/48 , A61K31/496 , A61K31/505 , A61K31/517 , A61P9/10 , A61P13/08 , A61P35/00 , C07D237/10 , A61K31/495
CPC分类号： A61K31/505
摘要： Methods are disclosed utilizing the optically pure (+) isomer of doxazosin. This compound is a potent drug for the treatment of benign prostatic hyperplasia while avoiding the concomitant liability of hypotensive effects associated with the racemic mixture of doxazosin.
摘要翻译：利用多沙唑嗪的光学纯（+）异构体公开了方法。该化合物是治疗良性前列腺增生的有效药物，同时避免与多沙唑嗪的外消旋混合物相关的降压作用的伴随责任。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式